A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma

Drug Delivery

Volumn 22, Issue 1, 2015, Pages 10-20

  Dai, Wenbing ^a   Fan, Yuchen ^a   Zhang, Hua ^a   Wang, Xueqing ^a   Zhang, Qiang ^a   Wang, Xinglin ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

B16 melanoma cells; Integrin receptors; IRGD; Neuropilin 1 receptors; Tumor penetrating

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; IRGD PEPTIDE; LIPOSOME; MACROGOL 2000; PENETRATION ENHANCING AGENT; UNCLASSIFIED DRUG; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; MACROGOL DERIVATIVE; N-END CYSTEINE PEPTIDE TUMOR-HOMING PEPTIDE; OLIGOPEPTIDE; PHOSPHATIDYLETHANOLAMINE;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG PENETRATION; FLOW CYTOMETRY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MALE; MELANOMA B16; MOUSE; NONHUMAN; TUMOR VASCULARIZATION; VASCULAR TUMOR; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; MELANOMA, EXPERIMENTAL; PATHOLOGY; TISSUE DISTRIBUTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; LIPOSOMES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; OLIGOPEPTIDES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION;

EID: 84920271862     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.903580     Document Type: Article

References (46)

1. Allen TM. (1998). Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56:747-56.
2. Allen TM. (2004). Cullis PR. Drug delivery systems: entering the mainstream. Science 303:1818-22.
3. Amin M, Badiee A, Jaafari MR. (2013). Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharm 458:324-33.
4. Bagri A, Tessier-Lavigne M, Watts RJ. (2009). Neuropilins in tumor biology. Clin Cancer Res 15:1860-4.
5. Becker PM, Waltenberger J, Yachechko R, et al. (2005). Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ Res 96:1257-65.
6. Bielenberg DR, Klagsbrun M. (2007). Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev 26:421-31.
7. Cairo CW, Gestwicki JE, Kanai M, et al. (2002). Control of multivalent interactions by binding epitope density. J Am Chem Soc 124:1615-9.
8. Dunne M, Zheng J, Rosenblat J, et al. (2011). APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. J Control Release 154:298-5.
9. Gabizon A, Shmeeda H, Horowitz AT, et al. (2004). Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177-92.
10. Geretti E, Shimizu A, Klagsbrun M. (2008). Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 11:31-9.
11. Graeven U, Rodeck U, Karpinski S, et al. (2000). Expression patterns of placenta growth factor in human melanocytic cell lines. J Invest Dermatol 115:118-23.
12. Gu F, Zhang L, Teply BA, et al. (2008). Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 105:2586-91.
13. Hood JD, Cheresh DA. (2002). Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100.
14. Huo M, Zou A, Yao C, et al. (2012). Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 33:6393-407.
15. Jin H, Varner J. (2004). Integrins: roles in cancer development and as treatment targets. Br J Cancer 90:561-5.
16. Kramer RH, Vu M, Cheng YF, et al. (1991). Integrin expression in malignant melanoma. Cancer Metastasis Rev 10:49-59.
17. Lasic DD. (1996). Doxorubicin in sterically stabilized liposomes. Nature 380:561-2.
18. Liu Y, Ji M, Wong MK, et al. (2013). Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery. Biomed Res Int 2013:378-80.
19. Lu Y, Wu J, Wu J, et al. (2007). Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm 4:707-12.
20. Marczak A, Kowalczyk A, Wrzesień-Kus A, et al. (2006). Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients. Cell Biol Int 30:127-32.
21. Minko T, Pakunlu RI, Wang Y, et al. (2006). New generation of liposomal drugs for cancer. Anticancer Agents Med Chem 6:537-52.
22. Mizejewski GJ. (1999). Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222:124-38.
23. Morelli D, Ménard S, Cazzaniga S, et al. (1997). Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug induced myelotoxicity in mice. Br J Cancer 75:659-9.
24. Nikolopoulos SN, Blaikie P, Yoshioka T, et al. (2004). Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 6:471-83.
25. Pellet-Many C, Frankel P, Jia H, et al. (2008). Neuropilins: structure, function and role in disease. Biochem J 411:211-26.
26. Schädlich A, Rose C, Kuntsche J, et al. (2011). How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurements. Pharm Res 28:1995-2007.
27. Sethuraman VA, Bae YH. (2007). TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 118:216-24.
28. Sharma P, Brown S, Walter G, et al. (2006). Nanoparticles for bioimaging. Adv Colloid Interface Sci 123-126:471-85.
29. Silvander M. (2002). Steric stabilization of liposomes - a review. Progr Colloid Polym Sci 120:35-40.
30. Slingerland M, Guchelaar HJ, Gelderblom H. (2012). Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 17:160-6.
31. Stephenson JM, Banerjee S, Saxena NK, et al. (2002). Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. Int J Cancer 101:409-14.
32. Sugahara KN, Teesalu T, Karmali PP, et al. (2009). Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:510-20.
33. Sugahara KN, Teesalu T, Karmali PP, et al. (2010). Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031-5.
34. Teesalu T, Sugahara KN, Ruoslahti E. (2013). Tumor-penetrating peptides. Front Oncol 27:216-23.
35. Wang X, Wang Y, Chen X, et al. (2009). NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. J Control Release 139:56-62.
36. Waite CL, Roth CM. (2011). Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density. Biotechnol Bioeng 108:2999-3008.
37. Xiang Y, Liang L, Wang X, et al. (2011). Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release 152:402-10.
38. Xiong XB, Huang Y, Lu WL, et al. (2005a). Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 107:262-75.
39. Xiong XB, Huang Y, Lu WL, et al. (2005b). Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 94:1782-93.
40. Yang T, Wang Y, Li Z, et al. (2012). Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine. 8:81-92.
41. Yang Z, Lei Z, Li B, et al. (2010). Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alpha-v integrin expression and up-regulating apoptosis signaling. Cancer Sci 101:494-500.
42. Ye Y, Zhu L, Ma Y, et al. (2011). Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging. Bioorg Med Chem Lett 21:1146-50.
43. Yu KF, Zhang WQ, Luo LM, et al. (2013). The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomedicine 8:2473-85.
44. Yue J, Liu S, Wang R, et al. (2012). Transferrin-conjugated micelles: enhanced accumulation and antitumor effect for transferrin-receptoroverexpressing cancer models. Mol Pharm 9:1919-31.
45. Zhang HT, Li HC, Li ZW, et al. (2011). A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo. Anticancer Drugs 22:409-15.
46. Zhu Z, Xie C, Liu Q, et al. (2011). The effect of hydrophilic chain length and iRGD on drug delivery from poly ("-caprolactone)-poly (N-vinylpyrrolidone) nanoparticles. Biomaterials 32:9525-35.